$4.50
-0.22%Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Chief Development Officer
Chief Executive Officer & Director
Compensation
$3,741,748
Chief Financial Officer
Chief Legal Officer
Compensation
$617,900
Chief Medical Officer & Head of Research
Compensation
$2,705,659
Chief Technical Officer
Compensation
$2,987,030
Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
Senior Vice President of Development Operations
Vice President & Corporate Controller
Vice President of Corporate Development
During the last 12 months, insiders have purchased $685K and sold $495K worth of LXEO shares, resulting in $190K of net buying activity.
0
0.00
59.6K
336.67K
-337K
-$337K
0
0.00
13.2K
84.22K
-84K
-$84K
2.2K
5.80K
3.7K
34.31K
-29K
-$29K
162.5K
679.24K
7.8K
39.89K
+639K
+$639K
Cooperstone Brenda
Director
$105K
Cholmondeley Paula H
Director
$105K
Altschuler Steven
Director
$105K
Agger Mette Kirstine
Director
$105K
Diaz Reinaldo M
Director
$105K
Townsend Richard Nolan
Director, Officer: Chief Executive Officer
$420K
Otero Jose Manuel
Officer: Chief Operating Officer
$53K
Adler Eric
Officer: Chief Medical Officer
$9K
Robertson Jenny
Officer: Chief Legal Officer
$8K
See Tai Sandi
Officer: Chief Development Officer
$6K
Moderately bullish with $190K net buying. Insiders show cautious optimism through measured share purchases.
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
LXEO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 30, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 28, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 26, 2024 | December 31, 2023 | 2023 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.